$PBYI
PUMA BIOTECHNOLOGY, INC.

2024 Q4 Form 10-Q Financial Statement

#000143774924033955 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $80.54M
YoY Change 43.53%
Cost Of Revenue $29.10M
YoY Change 119.04%
Gross Profit $51.45M
YoY Change 20.11%
Gross Profit Margin 63.87%
Selling, General & Admin $16.82M
YoY Change -26.24%
% of Gross Profit 32.69%
Research & Development $12.55M
YoY Change 9.62%
% of Gross Profit 24.39%
Depreciation & Amortization $100.0K
YoY Change 0.0%
% of Gross Profit 0.19%
Operating Expenses $29.37M
YoY Change -14.25%
Operating Profit $22.08M
YoY Change 157.18%
Interest Expense -$1.818M
YoY Change -154.45%
% of Operating Profit -8.23%
Other Income/Expense, Net -$1.471M
YoY Change -42.9%
Pretax Income $20.61M
YoY Change 242.95%
Income Tax $291.0K
% Of Pretax Income 1.41%
Net Earnings $20.32M
YoY Change 250.53%
Net Earnings / Revenue 25.23%
Basic Earnings Per Share $0.41
Diluted Earnings Per Share $0.41
COMMON SHARES
Basic Shares Outstanding 49.09M 49.05M
Diluted Shares Outstanding 49.17M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $96.73M
YoY Change 13.79%
Cash & Equivalents $67.26M
Short-Term Investments $29.46M
Other Short-Term Assets $236.0K
YoY Change -88.13%
Inventory $2.673M
Prepaid Expenses $2.540M
Receivables $54.64M
Other Receivables $0.00
Total Short-Term Assets $156.8M
YoY Change 25.1%
LONG-TERM ASSETS
Property, Plant & Equipment $601.0K
YoY Change -33.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.320M
YoY Change -21.45%
Total Long-Term Assets $63.90M
YoY Change -18.33%
TOTAL ASSETS
Total Short-Term Assets $156.8M
Total Long-Term Assets $63.90M
Total Assets $220.7M
YoY Change 8.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.509M
YoY Change 48.37%
Accrued Expenses $50.66M
YoY Change 50.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $45.33M
YoY Change 100.0%
Total Short-Term Liabilities $110.4M
YoY Change 63.89%
LONG-TERM LIABILITIES
Long-Term Debt $32.75M
YoY Change -57.27%
Other Long-Term Liabilities $121.0K
YoY Change -99.42%
Total Long-Term Liabilities $32.87M
YoY Change -57.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $110.4M
Total Long-Term Liabilities $32.87M
Total Liabilities $149.6M
YoY Change -9.24%
SHAREHOLDERS EQUITY
Retained Earnings -$1.334B
YoY Change -1.71%
Common Stock $1.405B
YoY Change 0.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $71.09M
YoY Change
Total Liabilities & Shareholders Equity $220.7M
YoY Change 8.41%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income $20.32M
YoY Change 250.53%
Depreciation, Depletion And Amortization $100.0K
YoY Change 0.0%
Cash From Operating Activities $11.04M
YoY Change 4.03%
INVESTING ACTIVITIES
Capital Expenditures $20.00K
YoY Change -33.33%
Acquisitions
YoY Change
Other Investing Activities $279.0K
YoY Change -97.51%
Cash From Investing Activities $259.0K
YoY Change -97.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -11.18M
YoY Change
NET CHANGE
Cash From Operating Activities 11.04M
Cash From Investing Activities 259.0K
Cash From Financing Activities -11.18M
Net Change In Cash 114.0K
YoY Change -99.48%
FREE CASH FLOW
Cash From Operating Activities $11.04M
Capital Expenditures $20.00K
Free Cash Flow $11.02M
YoY Change 4.14%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Registrant Name
EntityRegistrantName
PUMA BIOTECHNOLOGY, INC.
dei Entity Central Index Key
EntityCentralIndexKey
0001401667
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
760000 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
881000 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49067348
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49067348
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47646787
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47646787
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0 usd
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
2100000 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2400000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
7300000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
9700000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
9700000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
9700000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
9700000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
9700000 usd
CY2023Q3 us-gaap Depreciation
Depreciation
100000 usd
us-gaap Depreciation
Depreciation
300000 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2400000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
7300000 usd
pbyi Debt Instrument Exit Payment
DebtInstrumentExitPayment
2000000 usd
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35703
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0683487
dei Entity Address Address Line1
EntityAddressAddressLine1
10880 Wilshire Boulevard, Suite 2150
dei Entity Address City Or Town
EntityAddressCityOrTown
Los Angeles
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
90024
dei City Area Code
CityAreaCode
424
dei Local Phone Number
LocalPhoneNumber
248-6500
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
PBYI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
49087684
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67263000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
84585000 usd
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
29462000 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
11354000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
54643000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
47837000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
2673000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
7080000 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2540000 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4417000 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
236000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
912000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
156817000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
156185000 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5417000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7792000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
601000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
855000 usd
CY2024Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
53566000 usd
CY2023Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
60871000 usd
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2091000 usd
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2091000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
2229000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
2734000 usd
CY2024Q3 us-gaap Assets
Assets
220721000 usd
CY2023Q4 us-gaap Assets
Assets
230528000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
7509000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6889000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
50662000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
52721000 usd
CY2024Q3 pbyi Post Marketing Commitment Liability Current
PostMarketingCommitmentLiabilityCurrent
1550000 usd
CY2023Q4 pbyi Post Marketing Commitment Liability Current
PostMarketingCommitmentLiabilityCurrent
975000 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5347000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4800000 usd
CY2024Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
45329000 usd
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
33997000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
110397000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
99382000 usd
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
121000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
121000 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2948000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7034000 usd
CY2024Q3 pbyi Postmarketing Commitment Liability Noncurrent
PostmarketingCommitmentLiabilityNoncurrent
3421000 usd
CY2023Q4 pbyi Postmarketing Commitment Liability Noncurrent
PostmarketingCommitmentLiabilityNoncurrent
4890000 usd
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
32746000 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
65659000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
149633000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
177086000 usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
5000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
5000 usd
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1405248000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1398605000 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
26000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1334191000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1345164000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
71088000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
53442000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
220721000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
230528000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
80542000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
56116000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
171391000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
163459000 usd
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
29097000 usd
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
13284000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
50483000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
38359000 usd
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
16819000 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
22801000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
63541000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
69749000 usd
CY2024Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
12547000 usd
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
11446000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
39766000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
37509000 usd
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
58463000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
47531000 usd
us-gaap Costs And Expenses
CostsAndExpenses
153790000 usd
us-gaap Costs And Expenses
CostsAndExpenses
145617000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
22079000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
8585000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
17601000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
17842000 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1282000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
689000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
3498000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
1886000 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
3100000 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
3339000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
9831000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
9976000 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
347000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
74000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
594000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
118000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1471000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2576000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5739000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-7972000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
20608000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
6009000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
11862000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
9870000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
291000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
213000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
889000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
547000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
20317000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
5796000 usd
us-gaap Net Income Loss
NetIncomeLoss
10973000 usd
us-gaap Net Income Loss
NetIncomeLoss
9323000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.41
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.2
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.41
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.2
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49008464
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47520338
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48498579
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46977127
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49173361
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47819234
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49025103
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47397209
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
20317000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
5796000 usd
us-gaap Net Income Loss
NetIncomeLoss
10973000 usd
us-gaap Net Income Loss
NetIncomeLoss
9323000 usd
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
58000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
30000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
20375000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
5798000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
11003000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
9319000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
48509000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2054000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
150000 usd
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
58000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
20317000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
71088000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
30399000 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2545000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
0 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
5796000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
38742000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
53442000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6493000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
150000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
30000 usd
us-gaap Net Income Loss
NetIncomeLoss
10973000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
71088000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
21608000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7815000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
0 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000 usd
us-gaap Net Income Loss
NetIncomeLoss
9323000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
38742000 usd
us-gaap Net Income Loss
NetIncomeLoss
10973000 usd
us-gaap Net Income Loss
NetIncomeLoss
9323000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
8683000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
8630000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
6493000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
7815000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-121000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
514000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
625000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6685000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-10862000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-4407000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1153000 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-2382000 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-1379000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-676000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-441000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
620000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1379000 usd
pbyi Increase Decrease In Operating Lease Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilitiesNet
1164000 usd
pbyi Increase Decrease In Operating Lease Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilitiesNet
853000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-2059000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-18913000 usd
pbyi Increase Decrease In Postmarketing Commitment Liability
IncreaseDecreaseInPostmarketingCommitmentLiability
-894000 usd
pbyi Increase Decrease In Postmarketing Commitment Liability
IncreaseDecreaseInPostmarketingCommitmentLiability
-737000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
23311000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
16554000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
40000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
95000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
60956000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
12511000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
42878000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
14151000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
-0 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
12500000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-18118000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10955000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
150000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
22220000 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
-0 usd
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
445000 usd
us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
-0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-22515000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17322000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5599000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
86676000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
78792000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
69354000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
84391000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
20000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
us-gaap Interest Paid Net
InterestPaidNet
8483000 usd
us-gaap Interest Paid Net
InterestPaidNet
8721000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
1170000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
491000 usd
pbyi Number Of Subsidiaries
NumberOfSubsidiaries
1 pure
us-gaap Net Income Loss
NetIncomeLoss
11000000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
23300000 usd
CY2024Q3 pbyi Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
96700000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 pure
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;"><b>Use of Estimates: </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">The preparation of consolidated financial statements in conformity with Generally Accepted Accounting Principles (“GAAP”) in the United States, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the balance sheet, and reported amounts of revenues and expenses for the period presented. Accordingly, actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">Significant estimates include estimates for variable consideration for which reserves were established. These estimates are included in the calculation of net revenues and include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payors, and other indirect customers relating to the Company’s sale of its products.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p>
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6717964000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7414863000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6717964000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7438925000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
20317000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
5796000 usd
us-gaap Net Income Loss
NetIncomeLoss
10973000 usd
us-gaap Net Income Loss
NetIncomeLoss
9323000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49008464
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
47520338
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48498579
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
46977127
CY2024Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
164897
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
298896
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
526524
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
420082
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49173361
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47819234
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49025103
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
47397209
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.41
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.2
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.41
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.2
CY2024Q3 pbyi Sublease Agreement Potential Milestone Payments
SubleaseAgreementPotentialMilestonePayments
579800000 usd
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
2100000 usd
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
89907000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
31000 usd
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000 usd
CY2024Q3 pbyi Cash Cash Equivalents And Shortterm Investments Fair Value
CashCashEquivalentsAndShorttermInvestmentsFairValue
89932000 usd
CY2023Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
48916000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000 usd
CY2023Q4 pbyi Cash Cash Equivalents And Shortterm Investments Fair Value
CashCashEquivalentsAndShorttermInvestmentsFairValue
48912000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: left; text-indent: 0pt;"><b>Concentration of Risk: </b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents, marketable securities, and accounts receivable, net. The Company’s cash and cash equivalents and restricted cash in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured <span style="background-color:#ffffff;">limits at </span><em style="font: inherit;"> September 30, 2024</em><span style="background-color:#ffffff;"> were approximately </span>$68.6<span style="background-color:#ffffff;"> million. The Company does <em style="font: inherit;">not</em> believe it is exposed to any significant credit risk due to the nature of the financial instruments in which the money is held. Pursuant to the Company’s internal investment policy, investments must be rated A-<em style="font: inherit;">1/P</em>-<em style="font: inherit;">1</em> or better by Standard and Poor’s Rating Service and Moody’s Investors Service at the time of purchase.</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">The Company sells its products in the United States primarily through specialty pharmacies and specialty distributors. Therefore, wholesale distributors and large pharmacy chains account for a large portion of its accounts receivables, net and product revenues, net. The creditworthiness of its customers is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for doubtful accounts primarily based on the creditworthiness of its customers, historical payment patterns, aging of receivable balances and general economic conditions. </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;"><span style="background-color:#ffffff;">The Company also sells its products to international customers through sub-licensees. Royalty revenue consists of consideration earned related to international sales of NERLYNX made by the Company’s sub-licensees in their respective territories. A majority of the Company's royalty revenue is generated from sales into the China market.</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">The Company’s success depends on its ability to successfully commercialize NERLYNX. The Company currently has a single product and limited commercial sales experience, which makes it difficult to evaluate its current business, predict its future prospects and forecast financial performance and growth. The Company has invested a significant portion of its efforts and financial resources in the development and commercialization of the lead product, NERLYNX, and expects NERLYNX to constitute the vast majority of product revenue for the foreseeable future.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: left;">The Company relies exclusively on <em style="font: inherit;">third</em> parties to formulate and manufacture NERLYNX and its drug candidates. The commercialization of NERLYNX and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those <em style="font: inherit;">third</em> parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company has <em style="font: inherit;">no</em> experience in drug formulation or manufacturing and does <em style="font: inherit;">not</em> intend to establish its own manufacturing facilities. While the drug candidates were being developed by Pfizer, both the drug substance and drug product were manufactured by <em style="font: inherit;">third</em>-party contractors. The Company is using the same <em style="font: inherit;">third</em>-party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and the commercialization of NERLYNX and intends to use <em style="font: inherit;">third</em> party contractors to manufacture, supply, store and distribute drug supplies for its clinical trials of alisertib. If the Company is unable to continue its relationships with <em style="font: inherit;">one</em> or more of these <em style="font: inherit;">third</em>-party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p>
CY2024Q3 pbyi Cash And Cash Equivalents And Restricted Cash In Excess Of Insured Limits
CashAndCashEquivalentsAndRestrictedCashInExcessOfInsuredLimits
68600000 usd
CY2024Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
211000 usd
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
5693000 usd
CY2024Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2005000 usd
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
820000 usd
CY2024Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
457000 usd
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
567000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
2673000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
7080000 usd
CY2024Q3 pbyi Average Incremental Borrowing Rate
AverageIncrementalBorrowingRate
0.109 pure
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2400000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
7300000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
2400000 usd
CY2024Q3 pbyi Finitelived Intangible Asset Expected Amortization Year Six
FinitelivedIntangibleAssetExpectedAmortizationYearSix
2400000 usd
CY2024Q3 pbyi Trade Accounts Receivable Net Excluding License Revenue Receivable
TradeAccountsReceivableNetExcludingLicenseRevenueReceivable
29545000 usd
CY2023Q4 pbyi Trade Accounts Receivable Net Excluding License Revenue Receivable
TradeAccountsReceivableNetExcludingLicenseRevenueReceivable
27669000 usd
CY2024Q3 pbyi Royalty Revenue Receivable
RoyaltyRevenueReceivable
25858000 usd
CY2023Q4 pbyi Royalty Revenue Receivable
RoyaltyRevenueReceivable
21049000 usd
CY2024Q3 us-gaap Accounts Receivable Gross
AccountsReceivableGross
55403000 usd
CY2023Q4 us-gaap Accounts Receivable Gross
AccountsReceivableGross
48718000 usd
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
760000 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
881000 usd
CY2024Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
54643000 usd
CY2023Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
47837000 usd
CY2024Q3 pbyi Prepaid Cro Services Current
PrepaidCROServicesCurrent
37000 usd
CY2023Q4 pbyi Prepaid Cro Services Current
PrepaidCROServicesCurrent
6000 usd
CY2024Q3 pbyi Prepaid Other Clinical Development Current
PrepaidOtherClinicalDevelopmentCurrent
293000 usd
CY2023Q4 pbyi Prepaid Other Clinical Development Current
PrepaidOtherClinicalDevelopmentCurrent
534000 usd
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
289000 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1403000 usd
CY2024Q3 pbyi Prepaid Professional Fess Current
PrepaidProfessionalFessCurrent
579000 usd
CY2023Q4 pbyi Prepaid Professional Fess Current
PrepaidProfessionalFessCurrent
1081000 usd
CY2024Q3 us-gaap Prepaid Taxes
PrepaidTaxes
13000 usd
CY2023Q4 us-gaap Prepaid Taxes
PrepaidTaxes
0 usd
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1329000 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1393000 usd
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2540000 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4417000 usd
CY2024Q3 pbyi Prepaid Cro Services Noncurrent
PrepaidCROServicesNoncurrent
52000 usd
CY2023Q4 pbyi Prepaid Cro Services Noncurrent
PrepaidCROServicesNoncurrent
0 usd
CY2024Q3 pbyi Prepaid Insurance Noncurrent
PrepaidInsuranceNoncurrent
12000 usd
CY2023Q4 pbyi Prepaid Insurance Noncurrent
PrepaidInsuranceNoncurrent
0 usd
CY2024Q3 pbyi Prepaid Other Clinical Development Expense Noncurrent
PrepaidOtherClinicalDevelopmentExpenseNoncurrent
174000 usd
CY2023Q4 pbyi Prepaid Other Clinical Development Expense Noncurrent
PrepaidOtherClinicalDevelopmentExpenseNoncurrent
210000 usd
CY2024Q3 us-gaap Prepaid Expense Other Noncurrent
PrepaidExpenseOtherNoncurrent
1991000 usd
CY2023Q4 us-gaap Prepaid Expense Other Noncurrent
PrepaidExpenseOtherNoncurrent
2524000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
2229000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
2734000 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
4769000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
7151000 usd
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
3700000 usd
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
3700000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
4839000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.109 pure
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1463000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5983000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1508000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8954000 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
659000 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
8295000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
257000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
1044000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
266000 usd
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
1568000 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8576000 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8535000 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7975000 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7680000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
601000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
855000 usd
CY2024Q3 us-gaap Depreciation
Depreciation
100000 usd
us-gaap Depreciation
Depreciation
300000 usd
CY2024Q3 us-gaap Finite Lived License Agreements Gross
FiniteLivedLicenseAgreementsGross
102500000 usd
CY2023Q4 us-gaap Finite Lived License Agreements Gross
FiniteLivedLicenseAgreementsGross
102500000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
48934000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
41629000 usd
CY2024Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
53566000 usd
CY2023Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
60871000 usd
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2400000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
7300000 usd
CY2024Q3 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P5Y6M
CY2024Q3 pbyi Accrued Legal Verdict Expense Current
AccruedLegalVerdictExpenseCurrent
7971000 usd
CY2023Q4 pbyi Accrued Legal Verdict Expense Current
AccruedLegalVerdictExpenseCurrent
7706000 usd
CY2024Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
19239000 usd
CY2023Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
16496000 usd
CY2024Q3 pbyi Accrued Development Costs
AccruedDevelopmentCosts
1636000 usd
CY2023Q4 pbyi Accrued Development Costs
AccruedDevelopmentCosts
940000 usd
CY2024Q3 pbyi Accrued Variable Consideration Current
AccruedVariableConsiderationCurrent
9469000 usd
CY2023Q4 pbyi Accrued Variable Consideration Current
AccruedVariableConsiderationCurrent
9388000 usd
CY2024Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
5033000 usd
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
5900000 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4355000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4379000 usd
CY2024Q3 pbyi Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
845000 usd
CY2023Q4 pbyi Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
1044000 usd
CY2024Q3 pbyi Accrued Professional Fees Liability Current
AccruedProfessionalFeesLiabilityCurrent
633000 usd
CY2023Q4 pbyi Accrued Professional Fees Liability Current
AccruedProfessionalFeesLiabilityCurrent
245000 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1089000 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1589000 usd
CY2024Q3 pbyi Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
311000 usd
CY2023Q4 pbyi Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
4521000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
81000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
513000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
50662000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
52721000 usd
CY2024Q3 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
121000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
121000 usd
CY2024Q3 pbyi Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
121000 usd
CY2023Q4 pbyi Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
121000 usd
CY2024Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
50783000 usd
CY2023Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
52842000 usd
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
102000000 usd
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1261000 usd
CY2024Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
45329000 usd
us-gaap Extinguishment Of Debt Amount
ExtinguishmentOfDebtAmount
22664000 usd
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
32746000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
11332000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
45329000 usd
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
22674000 usd
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
79335000 usd
CY2024Q3 us-gaap Accumulated Amortization Deferred Finance Costs
AccumulatedAmortizationDeferredFinanceCosts
4149000 usd
CY2023Q4 us-gaap Accumulated Amortization Deferred Finance Costs
AccumulatedAmortizationDeferredFinanceCosts
3066000 usd
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1261000 usd
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
2344000 usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
64118
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
1356443
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
1197130
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2011Q4 pbyi Ordinary Shares Ownership Percentage
OrdinarySharesOwnershipPercentage
0.20 pure
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2054000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2545000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6493000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7815000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.57
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.17
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
706980
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.46
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
441430
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.57
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
105646
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
4.17
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
603817
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
3.75
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
438947
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
4.02
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1400000 usd
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1400000 usd
CY2014Q3 pbyi Milestone Payments Maximum Amount
MilestonePaymentsMaximumAmount
187500000 usd
CY2020Q2 pbyi Percentage Of Unpaid Portion Of Milestone Payments Interest Rate
PercentageOfUnpaidPortionOfMilestonePaymentsInterestRate
0.0625 pure
CY2021Q3 pbyi Milestone Payment
MilestonePayment
1800000 usd

Files In Submission

Name View Source Status
0001437749-24-033955-index-headers.html Edgar Link pending
0001437749-24-033955-index.html Edgar Link pending
0001437749-24-033955.txt Edgar Link pending
0001437749-24-033955-xbrl.zip Edgar Link pending
ex_722429.htm Edgar Link pending
ex_722430.htm Edgar Link pending
ex_722431.htm Edgar Link pending
ex_722432.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pbyi-20240930.xsd Edgar Link pending
pbyi20240930_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
pbyi-20240930_cal.xml Edgar Link unprocessable
pbyi-20240930_def.xml Edgar Link unprocessable
pbyi-20240930_lab.xml Edgar Link unprocessable
pbyi-20240930_pre.xml Edgar Link unprocessable
pbyi20240930_10q_htm.xml Edgar Link completed
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending